The Pharma Letter Sales of Zetia (ezetimibe) and Vytorin (ezetimibe/ simvastatin ), medicines for lowering LDL cholesterol, declined 3% to $1.0 billion, driven by lower sales of Vytorin, partially offset by growth of Zetia in the USA. Combined sales of Remicade (+6%) and ... and more »
MarketWatch Sales of ZETIA (ezetimibe) and VYTORIN (ezetimibe/ simvastatin ), medicines for lowering LDL cholesterol, declined 3 percent to $1.0 billion in the first quarter driven by lower sales of VYTORIN, partially offset by growth of ZETIA in the United States ...
